Aniracetam
A fat-soluble racetam reported to have anxiolytic as well as cognitive properties. Human evidence is limited and mostly older, drawn from studies in cognitive impairment; use in healthy adults rests largely on anecdote.
01 Overview
Aniracetam is a lipophilic analogue of piracetam developed in the 1970s. It has been studied in Europe and Japan as an adjunct in cognitive and mood disorders, but has not gained regulatory approval in most markets and is used largely as an unregulated nootropic.
Because it is lipid-soluble it crosses membranes readily but is rapidly metabolised, giving a short half-life. Reported benefits include mild anxiolytic effects alongside attention support, though controlled human data are thin.
02 Mechanism
Positively modulates AMPA glutamate receptors (an 'ampakine' action) and influences cholinergic and serotonergic/dopaminergic signalling; anxiolytic effects are attributed to the latter.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Typical nootropic | 750–1500 mg/day | Oral | Often split into 2 doses; taken with fat may aid absorption. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Mild anxiolytic effectUsers and some animal data suggest reduced anxiety; human trials are sparse. | Small | Anecdotal | |
| Attention / memory supportOlder clinical studies in impaired populations report modest gains. | Small, uncertain | Observational |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| HeadacheOccasional headache, sometimes linked to cholinergic demand. | Mild | Uncommon | Anecdotal | |
| Nausea / GI upsetMild stomach discomfort in some users. | Mild | Uncommon | Anecdotal |